Antibody Discovery + Bio-Native AI
Driven to solve.
Built for program outcomes.
MindWalk advances drug discovery through two flexible core offerings.
Science, technology and strategy built to address complex discovery needs, deliver deeper insight, and create stronger paths to program success.
Integrated drug discovery partnership
Antibody discovery and development customized to your scientific goals.
- Integrated advanced wet lab, data and AI solutions
- 20+ publicly disclosed client antibodies advanced to the clinic
- B cell Select® >98% discovery success rate*
- B cell Llama™, Hybridoma and yeast display discovery
- Flexible partnership models
Technology infrastructure
Build or extend your drug discovery technology stack.
- ReefIQ™ biological data substrate — connects fragmented discovery data and enriches it with biological context
- LensAI™ Bio-Native analytical application suite — AI applications spanning epitope mapping, paratyping, hit expansion, developability, immunogenicity, candidate evaluation, and more
Powered by HYFT® Technology, connecting 25B+ biological relationships to deepen biological context for AI reasoning.
ReefIQ at AMD Advancing AI 2026
MindWalk highlighted ReefIQ and its partnership with AMD in a leading area of life science technology: the data, compute, and infrastructure powering AI drug discovery at speed and scale. ReefIQ connects fragmented research data with biological context to strengthen AI reasoning.
B cell Llama™ VHH Discovery
MindWalk expanded its antibody discovery portfolio with B cell Llama™, a direct B cell VHH discovery platform that accesses the in vivo-matured camelid immune repertoire. The platform supports VHH discovery for bispecific, multispecific, and other therapeutic formats.
MindWalk obtains binding commitment for US $30M unsecured credit facility to fund biologics programs and ReefIQ commercial expansion
Fixed 7.00% rate. No financial maintenance covenants. No warrants or equity conversion features. No dilution to existing shareholders.
Epitope Mapping
Molecular precision aligned with x-ray crystallography. A recent LensAI case study shows computational insights reaching crystallographic-level accuracy for epitope mapping, highlighting how predictive context can strengthens experimental confidence.
CaseXCase
A series dedicated to LensAI in action. Each example applies biointelligence across discovery workflows—explore how analysis supports insight and measurable outcomes.
Darwin Inspired
Our brand is shaped by the principles of Darwin's daily walk of observation. MindWalk unites science and technology—a shared path shaped by curiousity and connection.
Integrated capabilities.
Connected around
your challenge.
We focus on the outcome your program needs and build the approach around delivering it. One multidisciplinary team stays with your program from design through molecule delivery, with direct access to the people doing the work. We offer flexible partnership structures and business terms to fit the program.
ReefIQ™ - Data substrate layer
Connect and trace discovery data across teams, systems, and workflows while adding biological context to reveal deeper relationships at speed and scale.
LensAI™ - Bio-Native suite
A suite of fit-for-purpose analytical AI applications that generate biological insight, assess candidate risk, and support better discovery and development decisions.
Advanced Lab Research
Integrated deep expertise in target analysis, discovery, characterization, engineering, and optimization to help advance stronger candidates.
Research highlights & innovation news
See latest updates: clinical trial, publications and patents
Across modalities, applications, and stages.
What people are saying:
“The MindWalk Rapid Prime immunization method and their downstream antibody discovery technology proved pivotal to Acumen's success, enabling timely identification of our human immunotherapeutic, sabirnetug, currently in Phase 2 clinical trials.”
Acumen Pharmaceuticals
“We partnered with MindWalk to generate specific binders against targets in autoimmunity and inflammation. Their proven expertise and customized discovery approach stood out immediately, and results from both their laboratory and LensAI platform exceeded expectations.”
GentiBio
“The B cell Select platform was central in developing our lead immunoinhibitory receptor drug candidates, which are now in phase I/II clinical trials. MindWalk's strategic approach, deep experience and technical know-how were essential to our discovery efforts.”
OncoResponse
“MindWalk’s LensAI platform, powered by HYFT technology, was central to optimizing our Pan-Amyloid Immunotherapy candidates for neurodegenerative disease. Their in silico screening, developability analysis, and protein engineering accelerated our discovery process and strengthened candidate performance.”
Amyl Therapeutics
The Vault™
Partner-ready therapeutic assets
A portfolio of AI-evolved assets across antibodies, vaccines, and beyond, ready to co-create or integrate.
Powered by experts
We are technologists and scientists working side by side. With deep experience in both, we deliver integrated solutions designed to shape the future of discovery.
Talk 1:1 with the team
Upcoming Events
Join us at an upcoming event.
World Bispecific Summit
Boston USA
Sep 16-17, 2026
BioTechX Europe 2026
Basel, Switzerland
Oct 6-8, 2026
Festival of Biologics 2026
Basel, Switzerland
Oct 13-15, 2026
AI-Driven Drug Discovery Summit 2026
Boston USA
Oct 27-29, 2026
PEGS Europe 2026
Lisbon, Portugal
Nov 17-19, 2026